Get our latest issue now

available for iOS, Android & web

latest issue

Vanda pulls EU filing for schizophrenia drug

Daily News | March 15, 2013

Kevin Grogan

The European Medicines Agency says it has been notified by Vanda Pharmaceuticals of the USA that it wants to withdraw its application for the schizophrenia drug Fanaptum (iloperidone) intended to be used for the treatment of schizophrenia.

The move comes as little surprise given that the agency's Committee for Medicinal Product for Human Use issued a negative opinion recommending against approval of Fanaptum in December last year. Vanda had requested a re-examination of the opinion in February but has now pulled the application.

The reason given is that the CHMP "identified missing data which will not be available in a timeframe acceptable in the centralised procedure". More details will be published after the monthly CHMP meeting starting March 18.

The drug has been marketed in North America by Novartis since 2010, as Fanapt, but in October, the Swiss major noted that it is discontinuing development on a long-acting injectable version.

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!